Top

Published in:

01-10-2019 | NSCLC | Research Paper

The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis

Authors: Jie Yang, Aimei Peng, Bo Wang, Aaron M. Gusdon, Xiaoting Sun, Gening Jiang, Peng Zhang

Published in: Clinical & Experimental Metastasis | Issue 5/2019

Abstract

This study aimed to identify the prognostic value of lymph node metastasis in patients with non-small cell lung cancer (NSCLC) and distant organ metastasis. A total of 42,613 NSCLC patients with distant metastasis from the surveillance, epidemiology, and end results database between 2010 and 2013 were included for analysis. The proportion of N0 stage in M1a patients was significantly higher than that in M1b patients, 34.0% and 22.7% respectively (P < 0.001). Compared with N0 patients, patients had higher odds of experiencing multiorgan metastases (MOM) if they had higher N stage at diagnoses (P < 0.001). The Kaplan–Meier curves suggested both M1a and M1b groups patients at stage N0 had better survival than those at higher N stage (P < 0.001). Further analysis indicated that better survival was observed in N0 stage compared with N2 or N3 stage if patients had bone metastasis, brain metastasis, or MOM (P < 0.001, P < 0.001, and P = 0.002, respectively), but there was no significant difference in survival among each N stage patients with liver metastasis only. Cox regression analysis showed that compared with N0 patients, higher hazard for disease-specific mortality was observed for patients with higher N stage. Among NSCLC patients with distant organ metastasis, lymph node metastasis was associated with higher odds of experiencing MOM and a worse prognosis in terms of longer survival except patients with liver metastasis. Better understandings of the role of lymphatic metastasis in M1 NSCLC could help clinicians with better management of the disease.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64(2):104–117. https://doi.org/10.3322/caac.21220 CrossRefPubMed

Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 13(8):790–801. https://doi.org/10.1016/S1470-2045(12)70211-5 CrossRefPubMed

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT (2017) The eighth edition lung cancer stage classification. Chest 151(1):193–203. https://doi.org/10.1016/j.chest.2016.10.010 CrossRefPubMed

Morgensztern D, Ng SH, Gao F, Govindan R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5(1):29–33. https://doi.org/10.1097/JTO.0b013e3181c5920c CrossRefPubMed

Rami-Porta R, Asamura H, Travis WD, Rusch VW (2017) Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):138–155. https://doi.org/10.3322/caac.21390 CrossRefPubMed

Yang J, Zhang Y, Sun X, Gusdon AM, Song N, Chen L, Jiang G, Huang Y (2018) The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study. J Cancer Res Clin Oncol 144(9):1835–1842. https://doi.org/10.1007/s00432-018-2702-9 CrossRefPubMed

Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, Fei K, Yang P, Xie D, Chen C (2016) Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget 7(33):53245–53253. https://doi.org/10.18632/oncotarget.10644 CrossRefPubMedPubMedCentral

Dai C, Ren Y, Xie D, Zheng H, She Y, Fei K, Jiang G, Chen C (2016) Does lymph node metastasis have a negative prognostic impact in patients with NSCLC and M1a disease? J Thorac Oncol 11(10):1745–1754. https://doi.org/10.1016/j.jtho.2016.06.030 CrossRefPubMed

10.

Johnson KK, Rosen JE, Salazar MC, Boffa DJ (2016) Outcomes of a highly selective surgical approach to oligometastatic lung cancer. Ann Thorac Surg 102(4):1166–1171. https://doi.org/10.1016/j.athoracsur.2016.04.086 CrossRefPubMed

11.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network (2015) Non-small cell lung cancer, Version 6.2015. J Natl Compr Cancer Netw 13(5):515–524CrossRef

12.

Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R, International Association for the Study of Lung Cancer S, Prognostic Factors Committee ABM, Participating I (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10(12):1675–1684. https://doi.org/10.1097/jto.0000000000000678 CrossRefPubMed

13.

Leung E, Xue A, Wang Y, Rougerie P, Sharma VP, Eddy R, Cox D, Condeelis J (2017) Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway. Oncogene 36(19):2680–2692. https://doi.org/10.1038/onc.2016.421 CrossRefPubMed

14.

Wong SY, Hynes RO (2006) Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 5(8):812–817. https://doi.org/10.4161/cc.5.8.2646 CrossRefPubMed

15.

Podgrabinska S, Skobe M (2014) Role of lymphatic vasculature in regional and distant metastases. Microvasc Res 95:46–52. https://doi.org/10.1016/j.mvr.2014.07.004 CrossRefPubMedPubMedCentral

16.

Brakenhielm E, Burton JB, Johnson M, Chavarria N, Morizono K, Chen I, Alitalo K, Wu L (2007) Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 121(10):2153–2161. https://doi.org/10.1002/ijc.22900 CrossRefPubMedPubMedCentral

17.

Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K, Wu L (2008) Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 68(19):7828–7837. https://doi.org/10.1158/0008-5472.CAN-08-1488 CrossRefPubMedPubMedCentral

18.

Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M (2006) Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66(5):2650–2657. https://doi.org/10.1158/0008-5472.CAN-05-1843 CrossRefPubMed

19.

Brown M, Assen FP, Leithner A, Abe J, Schachner H, Asfour G, Bago-Horvath Z, Stein JV, Uhrin P, Sixt M, Kerjaschki D (2018) Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 359(6382):1408–1411. https://doi.org/10.1126/science.aal3662 CrossRefPubMed

20.

Pereira ER, Kedrin D, Seano G, Gautier O, Meijer EFJ, Jones D, Chin SM, Kitahara S, Bouta EM, Chang J, Beech E, Jeong HS, Carroll MC, Taghian AG, Padera TP (2018) Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359(6382):1403–1407. https://doi.org/10.1126/science.aal3622 CrossRefPubMedPubMedCentral

21.

Osarogiagbon RU, Allen JW, Farooq A, Berry A, Spencer D, O’Brien T (2010) Outcome of surgical resection for pathologic N0 and Nx non-small cell lung cancer. J Thorac Oncol 5(2):191–196. https://doi.org/10.1097/JTO.0b013e3181c8cc32 CrossRefPubMed

22.

Osarogiagbon RU, Allen JW, Farooq A, Berry A, O’Brien T (2011) Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Ann Thorac Surg 91(5):1486–1492. https://doi.org/10.1016/j.athoracsur.2010.11.065 CrossRefPubMed

23.

Ohta Y, Oda M, Wu J, Tsunezuka Y, Hiroshi M, Nonomura A, Watanabe G (2001) Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis. J Thorac Cardiovasc Surg 122(5):900–906. https://doi.org/10.1067/mtc.2001.117626 CrossRefPubMed

24.

Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N (2015) Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 3(1):217–221. https://doi.org/10.3892/mco.2014.410 CrossRefPubMed

25.

Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86(1):78–84. https://doi.org/10.1016/j.lungcan.2014.07.020 CrossRefPubMed

Title: The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis
Authors: Jie Yang
Aimei Peng
Bo Wang
Aaron M. Gusdon
Xiaoting Sun
Gening Jiang
Peng Zhang
Publication date: 01-10-2019
Publisher: Springer Netherlands
Keywords: NSCLC
Metastasis
NSCLC
Published in: Clinical & Experimental Metastasis / Issue 5/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-09985-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Quantification of PpIX-fluorescence of cerebral metastases: a pilot study

Factors related to the quality of life in patients with bone metastases

Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

Keynote webinar | Spotlight on antibody–drug conjugates in cancer